Micra™ AV provides AV synchrony
allowing more of your patients to benefit from leadless pacing.2
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The Micra™ transcatheter pacing system (TPS) is the world’s smallest pacemaker,1 delivered percutaneously via a minimally invasive approach, directly into the right ventricle and does not require the use of leads.
The future is here
Allowing more of your patients to benefit from leadless pacing.
Parameter |
Micra AV5 |
Micra VR6 |
---|---|---|
Pacing Mode |
VVI, VVIR, VOO, OVO, VDD, VDI, ODO, OFF |
VVI, VVIR, VOO, OVO, OFF |
Mass |
1.75 g |
1.75 g |
Volume |
0.8 cc |
0.8 cc |
Electrode Spacing |
18 mm |
18 mm |
Battery Longevity |
8-13 years†5,7 |
12 years‡8 |
Accelerometer-based Mechanical Atrial Sensing |
Yes |
N/A |
Accelerometer-based Rate Response |
Yes |
Yes |
MRI SureScan™ |
1.5T & 3T |
1.5T & 3T |
The MARVEL 2 trial is a multicenter, pivotal IDE study in which the MARVEL 2 algorithm was downloaded into existing Micra™ VR devices in order to provide AV synchronous pacing.
Real-world experience reinforces safety and long-term performance of Micra™ VR.
Learn about the Micra VR design journey
More information (see more)
Less information (see less)
Micra AV transcatheter pacing system (TPS), the world smallest pacemaker
More information (see more)
Less information (see less)
Access interactive courses, videos, and educational resources to extend your knowledge on Micra™.
The single chamber Micra™ Transcatheter Pacing System is being described herein as Micra™ VR in order to distinguish it from Micra™ AV product. When information in this document related to both Micra AV and VR, “Micra™ Transcatheter Pacing Systems” is used to represent the portfolio of devices. Micra AV real world data not yet available.
Use conditions include:
8 years = 100% VDD pacing, 60 bpm, pacing threshold 1.5 V, impedance 500 Ω, pulse width 0.24 ms.
13 years = 15% VDD pacing, 70 bpm, pacing threshold 1.5 V, impedance 600 Ω, pulse width 0.24 ms.
Use conditions included: median pacing 53.5%, median pacing threshold 0.50 V, median impedance 543 Ω; 89% of patients with > 10-year projected longevity; 99% of patients with > 5-year longevity.12
Nippoldt D, Whiting J. Micra Transcatheter Pacing System Device Volume Characterization Comparison. November 2014. Medtronic data on file.
Medtronic Micra™ AV MC1AVR1 Reference Manual. March 2020.
Udo EO, Zuithoff NP, van Hemel NM, et al. Incidence and predictors of short- and long-term complications in pacemaker therapy: the FOLLOWPACE study. Heart Rhythm. May 2012;9(5):728-735.
Williams E, Whiting J. Micra Transcatheter Pacing System Size Comparison. November 2014. Medtronic data on file.
Medtronic Micra™ AV MC1AVR1 Device Manual. March 2020.
Medtronic Micra™ MC1VR01 Clinician Manual. April 2015.
Pender J, Whiting J. Micra AV Battery Longevity. January 2020. Medtronic data on file.
Duray GZ, Ritter P, El-Chami M et al. Long-term performance of a transcatheter pacing system: 12-Month Results from the Micra Transcatheter Pacing Study. Heart Rhythm. May 2017;14(5):702-709.
Reynolds D, Duray GZ, Omar R, et al. A Leadless Intracardiac Transcatheter Pacing System. N Engl J Med. February 11, 2016;374(6):533-541.
El-Chami MF, Al-Samadi F, Clementy N, et al. Updated performance of the Micra transcatheter pacemaker in the real-world setting: A comparison to the investigational study and a transvenous historical control. Heart Rhythm. December 2018;15(12):1800-1807.
Steinwender C, Khelae SK, Garweg C, et al. Atrioventricular synchronous pacing using a leadless ventricular pacemaker: Results from the MARVEL 2 Study. JACC Clin Electrophysiol. 2020;6(1):94-106.
Ritter P, et al. Long-Term Performance of a Transcatheter Pacing System: 12-month results from the Micra Global Clinical Trial. LBCT presentation at ESC 2016; Rome, Italy.